Press Releases

• Aug. 29, 2024

  Notable Labs to Present Data on September 4th at SOHO 2024

• Aug. 26, 2024

  Notable Labs Announces CEO Transition

• Jul. 24, 2024

  Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

• May. 9, 2024

  Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024

• Apr. 12, 2024

  Notable Labs Reports 2023 Financial Results and Provides a Business Update

• Apr. 9, 2024

  Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

• Apr. 8, 2024

  Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform

• Mar. 5, 2024

  Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform

• Feb. 22, 2024

  Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment

• Dec. 18, 2023

  Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome